Lisinopril Tablets.

Effects and efficacy:
Hypertension is used to treat essential hypertension and renovascular hypertension. It can be taken alone or in combination with other antihypertensive drugs. Congestive heart failure This product can be used in combination with digitalis or diuretics as an adjuvant treatment for congestive heart failure. Acute myocardial infarction This product is used to treat patients with stable hemodynamics within 24 hours after acute myocardial infarction, which can prevent the development of left ventricular dysfunction or heart failure and improve survival. Patients should receive routinely recommended treatments such as antithrombotics, aspirin and beta-blockers under appropriate conditions.

Usage and dosage:
This product should be taken orally once a day. Like other drugs that need to be taken once a day, this product should be taken at approximately the same time every day. The absorption of this product is not affected by food, and the doctor will adjust the dose individually according to the patient’s condition and blood pressure response. The treatment process using this product should always include an assessment of renal function. 1. For essential hypertension This product can be used alone or in combination with other types of antihypertensive drugs. Starting dose The routinely recommended initial dose for patients with essential hypertension is 10 mg per day. Patients with highly activated renin-angiotensin-aldosterone system (especially renovascular hypertension, hyposalinity or hypovolemia, cardiac decompensation, or severe hypertension) may experience excessive decrease in blood pressure after the first dose. The recommended starting dose for these patients is 2.5-5 mg, and treatment should be started under medical supervision. Patients with renal insufficiency require lower doses. Effective maintenance dose The effective maintenance dose is usually 20 mg once a day. Generally speaking, if the expected therapeutic effect is not achieved within 2 to 4 weeks of treatment, the dose can be further increased. The maximum dose used in long-term clinical controlled trials is 80 mg per day. Patients who are taking diuretics may experience symptomatic hypotension when using this product for the first time. Diuretics should be stopped two to three days before starting treatment with this product. For hypertensive patients who cannot stop taking diuretics, the initial dose of this product is 5 mg. Renal function and serum potassium should be monitored, and the dose of this product should be adjusted according to blood pressure. If necessary, diuretics can be resumed. The dose adjustment for patients with renal impairment is as follows, and the dose and/or frequency of administration should be adjusted according to blood pressure. The dose can be gradually increased to control blood pressure or to a maximum dose of 40 mg per day. The dose adjustment for patients with renal failure should be based on creatinine clearance; creatinine clearance (ml/min) less than 10, the initial dose is 2.5 mg/day; creatinine clearance (ml/min) between 10-30, the initial dose is 2.5-5 mg/day; creatinine clearance (ml/min) between 31-80, 5-10 mg/day. 2. Used for congestive heart failure For patients with symptomatic heart failure, as an adjunct to digitalis and diuretic therapy. The starting dose of this product is 2.5 mg, once a day, and it should be administered under clinical supervision to determine the initial effect on blood pressure. The dose should be adjusted according to the individual clinical response of the patient. The dose can be increased to the maximum dose tolerated by the patient under the guidance of a doctor, and the maximum dose should not exceed 35 mg, once a day. Note that the dose increase should not exceed 10 mg, and the increment interval should not be shorter than 2 weeks. 3. For acute myocardial infarction, if applicable, patients should receive standard recommended treatment, such as thrombolysis, aspirin and beta-adrenergic receptor blockers. This product can be used in combination with intravenous or transdermal nitroglycerin. Please follow the doctor’s advice for details. This product can be used within 24 hours of the onset of symptoms of myocardial infarction. The first dose is 5 mg orally, 5 mg is given 24 hours after the medication, 10 mg is given orally 48 hours later, and then 10 mg once a day. For patients with low systolic blood pressure (systolic blood pressure is 120mmHg or less), a lower dose (2.5mg) should be given at the beginning of treatment or within 3 days of infarction. If the systolic blood pressure is less than 100mmHg, treatment should not be started. The maintenance dose of this product is 10mg once a day. If hypotension occurs (systolic blood pressure is less than or equal to 100mmHg), a maintenance dose of 5mg per day can be given, and it can be temporarily reduced to 2.5mg if necessary. If hypotension persists (systolic blood pressure is less than 90mmHg for more than one hour), this product should be discontinued. The medication should be continued for six weeks, after which the patient’s condition should be reassessed. Patients who develop symptoms of heart failure should continue to use this product.

Adverse reactions:
Controlled clinical trials have shown that this product is generally well tolerated. In most cases, side effects are mild and transient. The most common side effects of this product in controlled trials are: dizziness, headache, diarrhea, fatigue, cough and nausea. Other rare side effects are: orthostatic effects (including hypotension), rash and weakness. Allergic/angioedema, angioedema of the face, limbs, lips, tongue, glottis and/or larynx has been reported occasionally. Side effects that occasionally occur in controlled clinical trials and after marketing include: Cardiovascular system: severe hypotension in high-risk patients may be secondary to myocardial infarction or cerebrovascular accident. Palpitations: tachycardia. Digestive system: abdominal pain, dyspepsia, dry mouth, hepatitis (hepatocellular or cholestatic), jaundice, pancreatitis. Nervous system: mental confusion, mood changes, paresthesia. Respiratory system: bronchospasm. Skin: peeling, sweating, itching, urticaria. Urogenital system: sexual dysfunction, decreased urine volume/anuria, acute renal failure, renal impairment, uremia. Reported as a group of comprehensive symptoms, including one or more of the following symptoms may occur: fever, vasculitis, myalgia, arthralgia/arthritis, ANA positive, elevated erythrocyte sedimentation rate, eosinophilia and leukocytosis, rash, photosensitivity or other skin symptoms may also occur. Laboratory findings Significant changes in standard laboratory parameters are rarely associated with taking this product. Increases in blood urea, blood creatinine, liver enzymes and serum bilirubin have been observed, and they often return to normal after stopping this product. Mild decreases in hemoglobin and hematocrit rarely have obvious clinical significance in the absence of other causes of anemia. Leukopenia and thrombocytopenia have been reported, but the causal relationship between this phenomenon and taking this product has not been established. Hyperkalemia has occurred. Hyponatremia has occurred.

Drug contraindications:
Allergy to this product is prohibited during pregnancy. Use with caution in case of renal impairment. Use with caution during lactation.